|
|
|
|
|
|
Andrew joined Health Advances in 2005 with a strong background in corporate strategy, finance, and strategic planning. At
Health Advances, Andrew has led dozens of projects for pharmaceutical and biotech companies, medical device
manufacturers, and private equity investors. He has particular expertise in helping companies formulate
clinical development, commercialization, and lifecycle management strategies to maximize the value of
therapeutics and franchises. He has worked across numerous therapeutic areas including autoimmune
diseases, oncology, CNS diseases, pulmonology, critical care, and orphan diseases. In
his nonprofit work, Andrew has assisted both the National Parkinson Foundation and the
Michael J. Fox Foundation with major strategic planning projects.
Prior to Health Advances, Andrew worked with Michael Porter of the Harvard Business School
on business strategy and healthcare policy, and with Monitor Group, where he split his time
between the Pharmaceutical and Corporate Finance practices. He also worked in Genentech's
internal strategic planning group. Andrew earned an AB in economics, summa cum laude, and a
minor in operations research from Princeton University, and an MBA with distinction from
the Harvard Business School.
|
|
 |
|
|
|
|
